# Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-carboplatin-plus-paclitaxel-as-the-first-second-and-third/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Maki Fujiwara,Shusuke Akamatsu,Takayuki Sumiyoshi,Takehiko Segawa,Kei Mizuno,Takayuki Yoshino,Takayuki Goto,Atsuro Sawada,Ryoichi Saito,Takashi Kobayashi,Toshinari Yamasaki,Takahiro Inoue,Osamu Ogawa |
| Citations | 12 |
| DOI | 10.1016/j.clgc.2019.04.017 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2949364885 |
| PMID | 31307917 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Atsuro Sawada](https://scholariq.org/researchers/atsuro-sawada/)

## Paper primary topic

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Paper topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.